This comparison evaluates deep learning architectures on binding affinity in immunotherapy, suggesting TCN outperforms LSTM and Transformers.
Accurate prediction of Major Histocompatibility Complex (MHC) class II-peptide binding affinity remains a critical challenge in immunotherapy and vaccine development due to the complexity of molecular interactions and allele-specific binding preferences. While existing computational approaches have shown promise, identifying the optimal deep learning architecture for this task remains an open question. This study addresses this gap by systematically comparing three state-of-the-art deep learning architectures: Long Short-Term Memory Networks (LSTM), Transformers, and Temporal Convolutional Networks (TCN) using the IEDB2016 dataset containing 134,281 MHC class II-peptide binding records. Our comprehensive evaluation employed five-fold cross-validation and ensemble modeling to assess both regression and classification performance. Results demonstrate that TCN consistently outperforms competing architectures, achieving superior regression metrics with R² of 0.6208 (vs. LSTM: 0.5923, Transformer: 0.5706) and classification performance with AUROC of 0.8766 (vs. LSTM: 0.8736, Transformer: 0.8707). Cross-validation confirmed TCN's robustness (average R²: 0.6229), while ensemble methods further validated its superiority (R²: 0.6805). These findings establish TCN as the most effective architecture for peptide-MHC binding prediction, offering significant implications for computational immunology and therapeutic design.
No takes yet. Share an insight, caveat, or question.
Pyakurel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: